Search Results

You are looking at 1 - 10 of 489 items for :

  • "paclitaxel" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221

Ciao-Sin Chen, Gary Zirpoli, William E. Barlow, G. Thomas Budd, Bryan McKiver, Lajos Pusztai, Gabriel N. Hortobagyi, Kathy S. Albain, M. Imad Damaj, Andrew K. Godwin, Alastair Thompson, N. Lynn Henry, Christine B. Ambrosone, Kathleen A. Stringer, and Daniel L. Hertz

Background Chemotherapy-induced peripheral neuropathy (CIPN) is the major treatment-limiting toxicity of many anticancer agents, including paclitaxel. CIPN affects up to 70% of paclitaxel-treated patients, and approximately 30% experience

Full access

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer

Matteo Lambertini, Marcello Ceppi, Richard A. Anderson, David A. Cameron, Marco Bruzzone, Maria Alice Franzoi, Claudia Massarotti, Sarra El-Abed, Yingbo Wang, Christophe Lecocq, Paolo Nuciforo, Rebecca Rolyance, Lajos Pusztai, Joohyuk Sohn, Maria Maddalena Latocca, Luca Arecco, Barbara Pistilli, Kathryn J. Ruddy, Alberto Ballestrero, Lucia Del Mastro, Fedro A. Peccatori, Ann H. Partridge, Cristina Saura, Michael Untch, Martine Piccart, Serena Di Cosimo, Evandro de Azambuja, and Isabelle Demeestere

standard of care for all patients. 1 – 3 In patients with node-negative small tumors, chemotherapy burden can be de-escalated by administering weekly paclitaxel for 3 months and concurrent trastuzumab for 1 year. 4 Considering its major negative impact

Full access

Delayed Recovery and Increased Severity of Paclitaxel-Induced Peripheral Neuropathy in Patients With Diabetes

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente, and Francisco Ayala de la Peña

-line taxanes also improve progression-free and overall survival. 3 Although myelosuppression is the major toxicity for docetaxel, 4 paclitaxel is more likely to be associated with dose-limiting peripheral neuropathy. 3 Paclitaxel-induced peripheral

Full access

Adherence to Hematologic Hold Parameters in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions

Marina Stasenko, R. Kevin Reynolds, Carolyn Johnston, Melissa Brackman, Karen McLean, and Shitanshu Uppal

peritoneal cancers undergo treatment consisting of both surgical debulking and chemotherapy. Conventional chemotherapy includes intravenous carboplatin and paclitaxel administered every 3 weeks for 6 cycles. 2 The Gynecologic Oncology Group (GOG)-172

Full access

Taxanes in the Adjuvant Treatment of Breast Cancer

Donna Trauth and Lori J. Goldstein

. 6 Nabholtz JM Gelmon K Bontenbal M . Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer . J Clin Oncol 1996 ; 14 : 1858 – 1867 . 7 Seidman A Hudis CA Albanel J . Dose

Full access

Intraperitoneal Chemotherapy for Ovarian Cancer: Where Are We Now?

Pankaj Singhal and Shashikant Lele

Cancer J Clin 2005 ; 55 : 10 – 30 . 2. McGuire WP Hoskins WJ Brady MF . Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the

Full access

Current Recommendations for Systemic Therapy of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury and David G. Pfister

Taxanes In the 1990s, taxanes showed impressive objective response rates (paclitaxel, 40%; docetaxel, 42%) in small nonrandomized studies for patients who had not undergone prior chemotherapy for R/M HNSCC. 21 , 22 In a randomized study (n = 218

Full access

CLO22-056: Phase I Trial of Concurrent Nab-paclitaxel and Cisplatin With Radiotherapy for Locally Advanced Cervical Cancer

Ping Jiang, Ang Qu, Weijuan Jiang, Xiuwen Deng, and Junjie Wang

Concurrent chemoradiotherapy using platinum-containing chemotherapy is the treatment of choice for stages IB3-IVA cervical cancer. A preclinical evaluation of the radiation-modulating effects of nab-paclitaxel in tumor showed that nab-paclitaxel

Full access

CLO22-081: Clinical Efficacy and Quality of Life of Oral Cancer Patients Treated With Paclitaxel/Cisplatin/5-FU Vs Paclitaxel/Carboplatin Chemotherapeutic Regimens in a Tertiary Cancer Center in Eastern India

Pranab Kumar Sahoo, Sinjini Sarkar, Sutapa Mahata, Ranita Pal, Tanuma Mistry, Sushmita Ghosh, Trisha Choudhury, Sriparna Datta, Anup Kumar Bhowmick, Kalyan Kusum Mukherjee, and Vilas D Nasare

to evaluate the clinical efficacy and QoL of paclitaxel/cisplatin/5-FU (TPF) vs paclitaxel/carboplatin (PC) chemotherapeutic regimens in the treatment of oral squamous cell carcinoma (OSCC) patients. Methods : Total 203 OSCC patients were recruited

Full access

CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde

Rasha Abo El Hassan, Noura Anwar Abdel-Fatah, Hadeer Khalefa Ahmed, May Shawki, and Lamia El Wkeel

risk factors for Paclitaxel induced peripheral neuropathy (PIPN). Methods : NCT03492047 is prospective randomized controlled open label study was conducted on 75 breast cancer patients receiving adjuvant paclitaxel 80 mg/m2 weekly for 12 weeks